A phase 2 trial in high-risk smoldering multiple myeloma found all 20 patients treated with cilta-cel became MRD-negative within two months and remained so after 15.3 months. No disease progression, death, dose-limiting toxicities, or high-grade side effects were observed.
A study of 366 patients found ide-cel CAR-T cell therapy achieved 81.6% overall response rate in patients 70 or older with relapsed/refractory multiple myeloma, with median progression-free survival of 18.9 months versus 5.7 months with standard regimens.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07713511 |
INfections in Patients Treated With CAR-T |
NOT_YET_RECRUITING | |
| NCT07094048 |
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager |
RECRUITING | PHASE4 |
